middle.news
Starpharma Secures $32 Million to Advance DEP® HER2-Lutetium Trial
9:49am on Tuesday 11th of August, 2026 AEST
•
Biotechnology
Read Story
Starpharma Secures $32 Million to Advance DEP® HER2-Lutetium Trial
9:49am on Tuesday 11th of August, 2026 AEST
Key Points
Fully underwritten 1-for-7.5 entitlement offer raises $32 million
99% take-up rate including $5.4 million oversubscription
Funds earmarked for DEP® HER2-Lutetium Phase 1 trial and oncology assets
56.1 million new shares to be allotted, ranking equally
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Starpharma (ASX:SPL)
OPEN ARTICLE